key: cord-0940346-mq4ch62v authors: Okubo, Keita; Iqbal, Sara; Lizaola-Mayo, Blanca; Aqel, Bashar; Graf, Erin H; Gea Banacloche, Juan C.; Singer, Andrew L; Harbell, Jack W title: A Case Report of Liver Transplant in a PCR-Positive COVID-19 Recipient date: 2021-07-29 journal: Transplant Proc DOI: 10.1016/j.transproceed.2021.07.045 sha: f8b07d02490665d46cfa579660c51a6592a7c37f doc_id: 940346 cord_uid: mq4ch62v SARS-CoV-2 virus (COVID-19) global pandemic has ushered us in an era of hesitation in performing transplants in affected patients. This stems from the paucity of data regarding the testing modalities, long term implications and uncertain prognosis in this group of patients. Current guidance from the Centers for Disease Control (CDC) recommends assessing symptoms rather than polymerase chain reaction (PCR) positivity. In light of these recommendations we describe a case of an orthotopic liver transplant (OLT) in a COVID-19 infected patient with persistent PCR positivity for 40 days prior to retransplant. Patient's perioperative and postoperative course was uncomplicated. Our experience leads us to advocate for liver transplants in COVID PCR positive patients after careful individualized and multidisciplinary evaluation in regards to their liver disease and COVID-19 symptomatology. Since the novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was found in Wuhan, China in December 2019, it has spread rapidly throughout the world. The disease caused by this virus, COVID-19 (acronym for Coronavirus Disease 2019) has affected more than 70 million people in 191 countries or regions and killed more than 1.7 million people and has been declared as a pandemic (1) . The American Society of Transplant Surgeons (ASTS) published guidelines in June 2020 to suspend organ transplants in symptomatic and asymptomatic infected individuals with positive PCR for SARS-CoV-2, as various studies have shown that surgery in these patients increases postoperative pulmonary complications and mortality (2) (3) . Additionally, acquiring COVID-19 as a transplant recipient is reported to have increased mortality (15-30%) , often atypical presentation, and a longer shedding phase with altered viral kinetics (4) (5) . As a result, many patients with positive COVID-19 have lost the opportunity to attain a transplant (6) . However, the recent guidelines from the CDC recommend formulating decisions regarding isolation on symptoms rather than PCR (7) . This is due to the fact that PCR may remain positive for weeks in the absence of viable virus (8) . We describe our first experience of a successful orthotopic liver transplant (OLT) in an asymptomatic patient with a persistently positive COVID-19 PCR prior to the transplant. A 65-year-old man with a past medical history significant for type 2 diabetes mellitus and NASH cirrhosis, complicated by ascites, non-bleeding esophageal varices, and hepatocellular carcinoma within Milan Criteria who underwent his OLT from a donation after circulatory death (DCD) donor in March 2020. He was maintained on immunosuppression with tacrolimus, mycophenolate and prednisone taper. Unfortunately, during work up of persistently elevated liver enzymes he underwent liver biopsy which was consistent with biliary outflow impairment along with periportal fibrosis without any features of rejection. Imaging studies confirmed biliary strictures which lead to multiple endoscopic retrograde cholangiopancreatographies (ERCPs) with minimal improvement. His liver enzymes continued to rise with total bilirubin ranging up to 35, alkaline phosphatase 1485, aminotransferases ranging 2-3 times the upper limit of normal. In view of rapid progression to cholestatic graft failure he was re-listed for liver transplant in August 2020. He was continued on tacrolimus monotherapy while he awaited an organ offer. He was found to be SARS-CoV-2 PCR positive on 8/13/2020 while he was worked up for a potential organ offer. Hence the transplant was aborted due to the concerns of active infection and his listing was changed to status 7, inactive for transplant. The patient was completely asymptomatic with a stable physical exam maintaining normal oxygen saturation. He denied fever, cough, shortness of breath, diarrhea, or alterations in his sense of taste or smell. Chest Xray ( Figure 1 ) and computed tomography without IV contrast was performed (Figure 2 ), despite lack of symptoms to ensure any signs of disease activity which showed patchy ground glass opacities along the peripheral aspects of the upper, as well as the left lower lobe, in association with architectural distortion mild bronchiectasis in the right upper and partly the lower lobes. It was felt these findings may represent pulmonary manifestations of COVID-19 pneumonia and after further review with our infectious disease colleagues, consensus was made to weekly check SARS-CoV-2 PCR until negative, to make patient active on the list. Serial testing over 40 days confirmed persistent positivity of the SARS-CoV-2 PCR as summarized in Table 1 and Figure 3 . All molecular testing was performed on nasopharyngeal swabs collected by a healthcare professional and in viral transport media. Two different Emergency Use Authorized testing platforms were used over the course of this patient's repeated testing: the Abbott m2000 SARS-CoV-2 RealTime assay and the Cepheid GeneXpert SARS-CoV-2 PCR. As a result, Ct values are not directly comparable between instruments, with the m2000 assay producing Ct values typically 10 cycles lower than the GeneXpert assay. Of note, the patient was staying at a hotel with his wife and son who did not develop COVID-19 and were completely asymptomatic. Furthermore, detection of SARS-CoV-2 antibodies on 9/2/20 suggested evidence of immunity and low transmissibility. The case was reviewed by the liver transplant multidisciplinary team and in the setting of progressive liver disease, rising MELD score and lack of COVID-19 symptoms, it was decided to re-activate him for transplant. Two days after being activated on the transplant list, he underwent liver re-transplant with a donation after brain death (DBD), public health service increased risk (PHS-IR) organ in late September. His surgery was performed in a negative pressure air cleaning system operation room. All the surgical staff had appropriate personal protective equipment (N-95 masks, gowns, hats, and shoe covers) for precaution. General endotracheal anesthesia was administered. Methylprednisolone 500 mg was given Mycophenolate mofetil (Cellcept) 2000mg/day, weight-based tacrolimus, and standard steroid taper was prescribed according to the protocol of our hospital. We didn't change our protocol especially to this patient. The rest of the postoperative course was unremarkable. He was discharged home with home health services on POD 10. The last follow up visit was on POD30 when his COVID PCR was negative. He was in an excellent clinical status. We report a case of an OLT in a patient with persistently positive SARS-CoV2 PCR with no symptoms of COVID-19. The transplant was successful, and no viral transmission was documented. Our case helps shed light on the dearth of data with regards to identifying the optimal time for transplantation in patients with SARS-CoV2 PCR positive. According to the latest AASLD expert consensus for transplants in SARS-CoV-2-positive candidates, they should be delayed for at least 14-21 days after symptom resolution and 1 or 2 negative SARS-CoV-2 diagnostic tests (9) . The likelihood of a replication-competent virus after 10 days of mild to moderate COVID-19 is very low (10) (11) . In some cases of severe Covid-19 infection, mostly complicated by immunocompromised state, recovery of replication-competent virus has been reported beyond 10 days but it is usually undetectable 20 days following symptom onset (12) . The recovered patient can continue to have SARS-CoV-2 RNA detected in their upper respiratory specimens for up to 12 weeks even though there is no replication-competent virus and no reported secondary infections from such patients (13) . Since this transplant was performed, there have been reported cases of isolation of replication competent virus for longer than 20 days in intensely immunosuppressed cancer patients (viable virus isolated on days 21, 25 and 64) (14) and in a severely immunocompromised lupus patient (15) . with COVID-19 emphasize that "Disease severity factors and the presence of immunocompromising conditions should be considered in determining the appropriate duration for specific patient populations." (16) . In this regard, it is important to point out that our patient seems to be a case of true asymptomatic SARS-CoV-2 infection, not a case of COVID-19. The exact proportion of asymptomatic SARS-CoV-2 infections is not known, but recent estimates are up to 40-45% (17) . In the small but well studied cohort of passengers of the Diamond Princess cruise ship 33 of 104 patients followed for 14 days after diagnosis were complete asymptomatic throughout the observation period (18) . Asymptomatic patients are sometimes conflated with "presymptomatic" patients, in part due to difficulties with study design (11) . This makes it difficult to ascertain the degree of infectiousness of both categories, which may be biologically dissimilar. Of note, our patient never had any symptoms, and his wife and son, who were staying with him at close quarters in a hotel room, did not develop symptoms of COVID-19 either. Although a false-positive PCR result is conceivable, the persistently positive PCR, development of anti-nucleocapsid SARS-CoV-2 antibodies and characteristic chest CT-findings support asymptomatic infection rather than a persistently false-positive PCR result. In our case continued immunosuppression since his previous transplant may have contributed to the persistent positivity of the SARS-CoC-2 PCR. Keeping that in mind we roughly doubled the AASLD recommended waiting period. This is also double the amount of time recommended by the CDC for severely immunocompromised patients who were asymptomatic throughout their infection (16) . Additionally, our patient had developed antibodies against SARS-CoV-2 three weeks after the PCR was detected. The presence of antibodies indicates a previous infection and some level of immunity or protection against Covid-19 re-infection albeit for an unknown duration (19) . A serum neutralizing antibody titer of at least 1:20 has been independently associated with noninfectious SARS-CoV-2 (12) . Our patient's antibody titers were later found to be undetectable hence he was advised to proceed with COVID-19 vaccination when it became available to him. He has done phenomenally well since his transplant with no major complications. We face an unusual challenge during the pandemic with the scarcity of empirical evidence to decide on solid organ transplants for COVID-19 positive patients. Although there was a decrease in the number of organ transplants being performed in the United States amid the COVID-19 outbreak, the number is beginning to increase (7) . The consensus in the transplant community has been the systematic use of polymerase chain reaction-based testing for both donors and recipients and in cases where recipients have a suspicion or active SARS-CoV-2 infection, it is advised to defer transplant for at least four weeks and after two negative tests at least 24 h apart (20) , however the optimal disease-free interval for a potential transplant recipient is not known. The decision should be individualized through a multidisciplinary approach to thoroughly evaluate all aspects of the case. The severity of SARS-CoV-2 infection as well as the appropriate utilization of quantitative viral load and serological assays should be considered to assess patient eligibility. It is equally important to take into account the severity and progression of the underlying liver disease and the risk of mortality if the transplant is delayed. It is encouraging to see increasing data revolving around outcomes in solid organ transplant recipients acquiring SARS-CoV-2 infection. However limited studies are available to provide evidence-based guidance regarding the time duration and eligibility of patients who get plagued by this disease before transplant. We hope this case report with its very favorable outcome serves to fill this void the transplant society currently faces. Chest computed tomography without IV contrast: Patchy ground-glass opacities with superimposed architectural distortion in the lung bases. Some mild fibrotic changes are thought to be related to COVID-19. Chest x-ray. No focal consolidation, pleural effusion, or pneumothorax. Normal heart size. Bibasilar atelectasis, right greater than left. Bibasilar reticular opacities were consistent with the architectural distortion seen on prior CT. Low lung volumes. The timeline of Ct value in SARS-CoV-2 RT-PCR. The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection Perioperative SARS-CoV-2 infections increase mortality, pulmonary complications, and thromboembolic events: A Dutch, multicenter, matched-cohort clinical study Covid-19 and Kidney Transplantation COVID-19 in solid organ transplant recipients: Initial report from the US epicenter Mortality rates in transplant recipients and transplantation candidates in a high prevalence COVID-19 environment HHS Announces New Organ Transplant Guidance | CDC Online Newsroom | CDC Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement Virological assessment of hospitalized patients with COVID-2019 Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility | NEJM Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. medRxiv Contact Tracing during Coronavirus Disease Outbreak Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host | NEJM Centers for Disease Control and Prevention Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis CDC. Information for Laboratories about Coronavirus Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach